$USNU
Elite Health Systems Inc.

2023 Q1 Form 10-K Financial Statement

#000114036123018265 Filed on April 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0%
Gross Profit $0.00 $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $130.0K $508.0K $1.386M
YoY Change -63.89% 104.84% 30.26%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $130.0K $508.0K $1.386M
YoY Change -63.89% 104.84% 20.52%
Operating Profit -$130.0K -$508.0K -$1.386M
YoY Change -63.89% 104.84% 1457.3%
Interest Expense $3.000K $1.140M $0.00
YoY Change -1050.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $3.000K -$147.0K
YoY Change -102.26% -68.39%
Pretax Income -$127.0K $632.0K -$1.533M
YoY Change -74.24% -267.64% 176.71%
Income Tax $0.00 $37.00K $39.00K
% Of Pretax Income 5.85%
Net Earnings -$108.0K $505.0K -$1.337M
YoY Change -74.35% -200.4% 113.24%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.17
Diluted Earnings Per Share -$0.01 $0.06 -$0.17
COMMON SHARES
Basic Shares Outstanding 7.842M 7.842M
Diluted Shares Outstanding 7.842M 7.842M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.281M $1.537M $1.537M
YoY Change -22.74% -29.43% -29.43%
Cash & Equivalents $1.281M $1.500M $1.537M
Short-Term Investments
Other Short-Term Assets $19.00K $18.00K $18.00K
YoY Change -59.57% -72.31% -72.31%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $1.300M $1.555M $1.555M
YoY Change -23.75% -30.67% -30.67%
LONG-TERM ASSETS
Property, Plant & Equipment $10.00K $20.00K $20.00K
YoY Change -79.59% -66.1% -66.1%
Goodwill $0.00
YoY Change -100.0%
Intangibles
YoY Change
Long-Term Investments $137.0K $157.0K $157.0K
YoY Change -6.16% 11.35% 11.35%
Other Assets $277.0K $172.0K $15.00K
YoY Change -71.3% -87.59% -98.39%
Total Long-Term Assets $287.0K $192.0K $192.0K
YoY Change -80.54% -86.71% -86.71%
TOTAL ASSETS
Total Short-Term Assets $1.300M $1.555M $1.555M
Total Long-Term Assets $287.0K $192.0K $192.0K
Total Assets $1.587M $1.747M $1.747M
YoY Change -50.09% -52.63% -52.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $65.00K $86.00K $86.00K
YoY Change -63.28% -49.11% -49.11%
Accrued Expenses $12.00K $23.00K $23.00K
YoY Change -72.73% -46.51% -46.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $247.0K $280.0K $280.0K
YoY Change -60.42% -55.27% -55.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $11.00K $11.00K $11.00K
YoY Change -52.17% -67.65% -67.65%
Total Long-Term Liabilities $11.00K $11.00K $11.00K
YoY Change -52.17% -67.65% -67.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $247.0K $280.0K $280.0K
Total Long-Term Liabilities $11.00K $11.00K $11.00K
Total Liabilities $258.0K $291.0K $508.0K
YoY Change -74.83% -55.91% -54.32%
SHAREHOLDERS EQUITY
Retained Earnings -$1.818M -$1.710M
YoY Change 358.45%
Common Stock $2.949M $2.949M
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.131M $1.239M $1.239M
YoY Change
Total Liabilities & Shareholders Equity $1.587M $1.747M $1.747M
YoY Change -50.09% -52.63% -52.63%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$108.0K $505.0K -$1.337M
YoY Change -74.35% -200.4% 113.24%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$130.0K -$272.0K -$1.413M
YoY Change -61.31% 1.49% -912.07%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$126.0K $1.158M $772.0K
YoY Change -31.52% -1057.02% 1125.4%
Cash From Investing Activities -$126.0K $1.158M $772.0K
YoY Change -31.52% -1057.02% 1125.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -130.0K -272.0K -1.413M
Cash From Investing Activities -126.0K 1.158M 772.0K
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -256.0K 886.0K -641.0K
YoY Change -50.77% -327.76% -533.11%
FREE CASH FLOW
Cash From Operating Activities -$130.0K -$272.0K -$1.413M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Accounts Receivable Related Parties Noncurrent
AccountsReceivableRelatedPartiesNoncurrent
15000
CY2021Q4 us-gaap Accounts Receivable Related Parties Noncurrent
AccountsReceivableRelatedPartiesNoncurrent
930000
CY2022Q4 us-gaap Goodwill
Goodwill
0
CY2021Q4 us-gaap Goodwill
Goodwill
315000
CY2021 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
0
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
0
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2022 us-gaap Advertising Expense
AdvertisingExpense
0
CY2021 us-gaap Advertising Expense
AdvertisingExpense
0
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
59000
CY2022Q4 usnu Total Leased Assets Operating And Financing
TotalLeasedAssetsOperatingAndFinancing
20000
CY2021Q4 usnu Total Leased Assets Operating And Financing
TotalLeasedAssetsOperatingAndFinancing
59000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
43000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23000
CY2022Q4 usnu Total Lease Liabilities Operating And Finance
TotalLeaseLiabilitiesOperatingAndFinance
23000
CY2021Q4 usnu Total Lease Liabilities Operating And Finance
TotalLeaseLiabilitiesOperatingAndFinance
66000
CY2022 us-gaap Lease Cost
LeaseCost
41000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
24000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
24000
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0585
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001089815
CY2022 dei Auditor Firm
AuditorFirmId
3233
CY2021 dei Auditor Firm
AuditorFirmId
517
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
0-15586
CY2022 dei Entity Registrant Name
EntityRegistrantName
U.S. NeuroSurgical Holdings, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-5370333
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
2400 Research Blvd, Suite 325
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
CY2022 dei City Area Code
CityAreaCode
301
CY2022 dei Local Phone Number
LocalPhoneNumber
208-8998
CY2022 dei Security12g Title
Security12gTitle
Common Stock, par value $.01 per share
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
811000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7842185
CY2022 dei Auditor Name
AuditorName
Mercurius & Associates LLP
CY2022 dei Auditor Location
AuditorLocation
New Delhi, India
CY2021 dei Auditor Name
AuditorName
ARONSON LLC
CY2021 dei Auditor Location
AuditorLocation
Rockville, Maryland
CY2022 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
0
CY2021 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
86000
CY2022 us-gaap Sales Type Lease Interest Income
SalesTypeLeaseInterestIncome
0
CY2021 us-gaap Sales Type Lease Interest Income
SalesTypeLeaseInterestIncome
8000
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
16000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-19000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3686000
CY2021 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
315000
CY2021 us-gaap Profit Loss
ProfitLoss
-973000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3028000
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
0
CY2022 us-gaap Profit Loss
ProfitLoss
-1572000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1456000
CY2022 us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
-116000
CY2021 us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
-470000
CY2022 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0
CY2021 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2022 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
2000
CY2021 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0
CY2022 usnu Income Loss From Equity Method Investments Net
IncomeLossFromEquityMethodInvestmentsNet
-1244000
CY2022 us-gaap Proceeds From Collection Of Lease Receivables
ProceedsFromCollectionOfLeaseReceivables
0
CY2021 us-gaap Proceeds From Collection Of Lease Receivables
ProceedsFromCollectionOfLeaseReceivables
532000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
211000
CY2022 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
0
CY2021 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
315000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1500000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
420000
CY2021 us-gaap Lease Cost
LeaseCost
34000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
24000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
0
CY2022 usnu Renovation Installation And Operation Agreement Period
RenovationInstallationAndOperationAgreementPeriod
P14Y
CY2018Q3 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
2447000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
228000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
39000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
192000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
39000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
420000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-322000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-130000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-101000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-106000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
246000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-67000
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
2000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
216000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
721000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
420000
CY2022Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
654000
CY2021Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
587000
CY2022Q4 usnu Deferred Tax Assets Intangible Assets And Other Capitalized Costs
DeferredTaxAssetsIntangibleAssetsAndOtherCapitalizedCosts
-1000
CY2021Q4 usnu Deferred Tax Assets Intangible Assets And Other Capitalized Costs
DeferredTaxAssetsIntangibleAssetsAndOtherCapitalizedCosts
102000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
344000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
66000
CY2022Q4 usnu Deferred Tax Assets Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxAssetsNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
19000
CY2021Q4 usnu Deferred Tax Assets Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxAssetsNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
45000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1016000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
800000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
0
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
0
CY2019 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
176000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
161000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
24000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
66000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
59000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
41000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
42000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
24000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
24000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
24000
CY2022 us-gaap Malpractice Insurance Annual Coverage Limit
MalpracticeInsuranceAnnualCoverageLimit
3000000

Files In Submission

Name View Source Status
0001140361-23-018265-index-headers.html Edgar Link pending
0001140361-23-018265-index.html Edgar Link pending
0001140361-23-018265.txt Edgar Link pending
0001140361-23-018265-xbrl.zip Edgar Link pending
brhc10051212_10k.htm Edgar Link pending
brhc10051212_ex31-1.htm Edgar Link pending
brhc10051212_ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
brhc10051212_10k_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usnu-20221231.xsd Edgar Link pending
usnu-20221231_def.xml Edgar Link unprocessable
usnu-20221231_pre.xml Edgar Link unprocessable
usnu-20221231_lab.xml Edgar Link unprocessable
usnu-20221231_cal.xml Edgar Link unprocessable